China News Service, Shanghai, February 3 (Reporter Li Shuzheng) The Lingang New Area of Shanghai Free Trade Zone (hereinafter referred to as the Lingang New Area) is accelerating the construction of a biomedical industry innovation highland with global influence.
On the 3rd, 15 biomedical projects were signed in the Lingang New Area, with a total investment of over 15 billion yuan (RMB, the same below).
In this signing event, a number of heavyweight biopharmaceutical companies including Hebo Pharmaceutical, Xinwei Medical, and Jinfang Pharmaceutical have settled in the new area. 15 projects cover innovative biological drugs, key vaccines, high-end medical devices, CRO/ CDMO services and other fields have a total investment of more than 15 billion yuan.
According to officials here, this is the first concentrated signing event for a special biomedicine session in the year when Shanghai’s "14th Five-Year Plan" was launched, and it was also the first large-scale "handover" event after the opening of the "Blue Bay of Life" in the Lingang New Area.
The biopharmaceutical industry is a key area of strategic emerging industries and one of the “four key industries” in the Lingang New Area.
As one of the 26 characteristic parks in Shanghai, "Life Blue Bay" has become an important platform for the biomedical industry in the new district.
In the past year, the Lingang New Area has successively introduced key projects including Shanghai Organic Research Institute, Heyuan, Dejian, Duchuang, WuXi AppTec, Opium, Le Chunle, etc. through chain supplement, strong chain, fixed chain and chain extension , There are nearly 60 biomedical companies, which have formed a leading position in quantity and a head effect in quality.
In addition, through deepening policy innovation, the new area has released several measures for the development of the biomedical industry in the new version 2.0, precisely focusing on key core R&D breakthroughs, clinical listings, large-scale support and other industrial development needs at various stages.
The latest data shows that since its establishment in August 2019, more than 50 projects in the biomedical industry in Lingang New Area have been implemented, with an investment of 20.86 billion yuan.
(Finish)